E P Brass

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Changing the status of drugs from prescription to over-the-counter availability
    E P Brass
    Department of Medicine, Harbor UCLA Medical Center, Torrance, Calif 90502, USA
    N Engl J Med 345:810-6. 2001
  2. ncbi request reprint Carnitine and sports medicine: use or abuse?
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, 1124 West Carson Street, Building J2, Torrance, CA 90502, USA
    Ann N Y Acad Sci 1033:67-78. 2004
  3. doi request reprint Intermittent claudication: new targets for drug development
    Eric P Brass
    Department of Medicine, Center for Clinical Pharmacology, Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    Drugs 73:999-1014. 2013
  4. doi request reprint Improving the decision-making process for nonprescription drugs: a framework for benefit-risk assessment
    E P Brass
    Department of Medicine, Harbor UCLA Medical Center, Torrance, California, USA
    Clin Pharmacol Ther 90:791-803. 2011
  5. doi request reprint A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, Torrance, CA 90502, USA
    J Vasc Surg 55:381-389.e1. 2012
  6. pmc Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication
    Roger J Lewis
    Department of Emergency Medicine, Harbor UCLA Medical Center, 1000 West Carson Street, Torrance, California 90509, USA
    Trials 12:134. 2011
  7. ncbi request reprint Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease
    E P Brass
    Department of Medicine, Harbor University of California Los Angeles Medical Center, Torrance, California 90509, USA
    Am J Physiol Heart Circ Physiol 280:H603-9. 2001
  8. ncbi request reprint Potential impact on cardiovascular public health of over-the-counter statin availability
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, Torrance, California, USA
    Am J Cardiol 97:851-6. 2006
  9. ncbi request reprint Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia
    Eric P Brass
    Harbor UCLA Medical Center for Clinical Pharmacology, Torrance, California 90502, USA
    J Vasc Surg 43:752-9. 2006
  10. ncbi request reprint The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease
    Eric P Brass
    Department of Medicine, Harbor UCLA Medical Center, Torrance, California 90502, USA
    J Am Coll Cardiol 48:2539-45. 2006

Detail Information

Publications39

  1. ncbi request reprint Changing the status of drugs from prescription to over-the-counter availability
    E P Brass
    Department of Medicine, Harbor UCLA Medical Center, Torrance, Calif 90502, USA
    N Engl J Med 345:810-6. 2001
    ..Thus, the future promises increases in the number of drugs available over the counter and in the variety of indications for their use...
  2. ncbi request reprint Carnitine and sports medicine: use or abuse?
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, 1124 West Carson Street, Building J2, Torrance, CA 90502, USA
    Ann N Y Acad Sci 1033:67-78. 2004
    ..While data do not allow a conclusion to be drawn that carnitine is beneficial, the negative has not been proven either...
  3. doi request reprint Intermittent claudication: new targets for drug development
    Eric P Brass
    Department of Medicine, Center for Clinical Pharmacology, Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    Drugs 73:999-1014. 2013
    ..Translation of these opportunities into effective therapeutics will be important as the already high prevalence of PAD is expected to increase as the population ages...
  4. doi request reprint Improving the decision-making process for nonprescription drugs: a framework for benefit-risk assessment
    E P Brass
    Department of Medicine, Harbor UCLA Medical Center, Torrance, California, USA
    Clin Pharmacol Ther 90:791-803. 2011
    ..The proposed approach has the potential to provide structured, transparent tools for regulatory decision making for nonprescription drugs...
  5. doi request reprint A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, Torrance, CA 90502, USA
    J Vasc Surg 55:381-389.e1. 2012
    ..K-134, a novel phosphodiesterase inhibitor, was evaluated in a phase II trial incorporating an adaptive design to assess its safety, tolerability, and effect on treadmill walking time...
  6. pmc Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication
    Roger J Lewis
    Department of Emergency Medicine, Harbor UCLA Medical Center, 1000 West Carson Street, Torrance, California 90509, USA
    Trials 12:134. 2011
    ..We describe the design, oversight, and implementation of an adaptive, phase II, dose-finding trial evaluating K-134 for the treatment of stable, intermittent claudication...
  7. ncbi request reprint Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease
    E P Brass
    Department of Medicine, Harbor University of California Los Angeles Medical Center, Torrance, California 90509, USA
    Am J Physiol Heart Circ Physiol 280:H603-9. 2001
    ....
  8. ncbi request reprint Potential impact on cardiovascular public health of over-the-counter statin availability
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, Torrance, California, USA
    Am J Cardiol 97:851-6. 2006
    ..The analyses also identified opportunities for optimizing the use of OTC statins in the marketplace...
  9. ncbi request reprint Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia
    Eric P Brass
    Harbor UCLA Medical Center for Clinical Pharmacology, Torrance, California 90502, USA
    J Vasc Surg 43:752-9. 2006
    ..The current trial was designed to test the hypothesis that lipo-ecraprost would improve amputation-free survival in patients with CLI who had no revascularization options...
  10. ncbi request reprint The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease
    Eric P Brass
    Department of Medicine, Harbor UCLA Medical Center, Torrance, California 90502, USA
    J Am Coll Cardiol 48:2539-45. 2006
    ..The current study tested the hypothesis that NM-702 improves treadmill exercise performance in peripheral arterial disease patients with claudication-limited exercise performance...
  11. ncbi request reprint Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, 1124 W Carson Street, Torrance, CA 90502, USA
    Vasc Med 11:141-5. 2006
    ..The current analyses provide benchmark data for ensuring that development programs are large enough to allow meaningful safety conclusions, and to assist in data and safety monitoring of these trials...
  12. ncbi request reprint Optimal assessment of baseline treadmill walking performance in claudication clinical trials
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, 1124 W Carson Street, Torrance, CA 90502, USA
    Vasc Med 12:97-103. 2007
    ..These characteristics may obviate the need for multiple treadmill tests, potentially saving study costs and improving patient acceptance of trial participation...
  13. doi request reprint Can consumers self-select for appropriate use of an over-the-counter statin? The Self Evaluation of Lovastatin to Enhance Cholesterol Treatment Study
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, Torrance, California, USA
    Am J Cardiol 101:1448-55. 2008
    ..In conclusion, SELECT showed that consumers could use an OTC drug label in an unsupervised setting to appropriately self-select for self-management of their cholesterol with lovastatin...
  14. doi request reprint Analysis of multiple end points in consumer research in support of switching drugs from prescription to over-the-counter status: the concept of end-point hierarchies
    E P Brass
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Clin Pharmacol Ther 85:369-74. 2009
    ....
  15. doi request reprint Temporal pattern of skeletal muscle gene expression following endurance exercise in Alaskan sled dogs
    Eric P Brass
    Department of Medicine, Harbor University of California Los Angeles Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    J Appl Physiol (1985) 107:605-12. 2009
    ..RNA expression profiling has the potential to identify novel regulatory mechanisms and responses to exercise stimuli...
  16. pmc Basic biomedical sciences and the future of medical education: implications for internal medicine
    Eric P Brass
    Department of Medicine, Harbor UCLA Medical Center and the David Geffen School of Medicine at UCLA, 1124 W Carson Street, Torrance, CA 90502, USA
    J Gen Intern Med 24:1251-4. 2009
    ..Internists should be engaged in the ongoing discussions of medical education reform and provide a strong voice in support of rigorous scientific training for the profession...
  17. doi request reprint Considerations in the development of drugs to treat sarcopenia
    Eric P Brass
    Department of Medicine, Harbor University of California at Los Angeles Medical Center, Torrance, California, USA
    J Am Geriatr Soc 59:530-5. 2011
    ..Each potential endpoint has advantages and disadvantages from scientific, clinical, and regulatory perspectives that must be carefully considered in the design of trials for sarcopenia treatments...
  18. ncbi request reprint Pivalate-generating prodrugs and carnitine homeostasis in man
    Eric P Brass
    Department of Medicine, Harbor University of California Los Angeles Medical Center, Torrance, California 90502, USA
    Pharmacol Rev 54:589-98. 2002
    ..In contrast, long-term treatment with substantial doses of pivalate prodrugs may require administration of carnitine supplementation to avoid carnitine depletion...
  19. ncbi request reprint Label development and the label comprehension study for over-the-counter drugs
    Eric P Brass
    Department of Medicine, Center for Clinical Pharmacology, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Clin Pharmacol Ther 74:406-12. 2003
  20. ncbi request reprint Implications of a switch from prescription to over-the-counter status for allergy drugs
    Eric P Brass
    Department of Medicine, Harbor UCLA Center for Clinical Pharmacology, 1124 W Carson Street, Tornace, CA 90502, USA
    Curr Allergy Asthma Rep 4:245-50. 2004
    ..Therefore, although OTC access to allergy medications facilitates treatment of allergies by consumers, more research is required to understand the true public health and economic impacts of OTC availability of these drugs...
  21. ncbi request reprint Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, Torrance, CA 90502
    Clin Pharmacol Ther 73:338-47. 2003
    ..To evaluate the effect of pivalate prodrug treatment on carnitine homeostasis, we administered a pivalate prodrug, cefditoren pivoxil, to healthy subjects and performed carnitine balance studies...
  22. ncbi request reprint Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients
    E P Brass
    Department of Medicine, Harbor University of California at Los Angeles Medical Center, Torrance, CA 90509, USA
    Am J Kidney Dis 37:1018-28. 2001
    ..VO(2max) in the primary analysis and other assessed end points were unaffected by carnitine therapy...
  23. ncbi request reprint Consumer behavior in the setting of over-the-counter statin availability: lessons from the consumer use study of OTC Mevacor
    Eric P Brass
    Department of Medicine, Center for Clinical Pharmacology, Harbor UCLA Medical Center, Torrance, California 90502, USA
    Am J Cardiol 94:22F-29F. 2004
    ..These data are important for making an informed risk-benefit decision concerning OTC statin availability...
  24. ncbi request reprint Peripheral arterial disease is not associated with an increased prevalence of intradialytic cramps in patients on maintenance hemodialysis
    Eric P Brass
    Department of Medicine, Harbor UCLA Medical Center, Torrance, Calif 90502, USA
    Am J Nephrol 22:491-6. 2002
    ..Peripheral arterial disease (PAD) has been suggested as a contributing factor to the development of intradialytic muscle cramps in patients on maintenance hemodialysis...
  25. ncbi request reprint Clinical and demographic predictors of exercise capacity in end-stage renal disease
    Kathy E Sietsema
    Department of Medicine, Harbor UCLA Research and Education Institute, Torrance, CA, USA
    Am J Kidney Dis 39:76-85. 2002
    ....
  26. pmc Synthetic peptides that exert antimicrobial activities in whole blood and blood-derived matrices
    Michael R Yeaman
    Department of Medicine, Division of Infectious Diseases, Harbor UCLA Medical Center, Research and Education Institute at Harbor UCLA, Torrance, California 90502, USA
    Antimicrob Agents Chemother 46:3883-91. 2002
    ..Collectively, these findings support the concept that synthetic peptides can be designed to exert potent antimicrobial activities in relevant and complex biological matrices...
  27. ncbi request reprint Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpoint discussion
    Eric P Brass
    Center for Clinical Pharmacology, Department of Medicine, Harbor UCLA Medical Center, Torrance, CA, USA
    Vasc Med 9:293-301. 2004
    ..The relative contribution of these factors and their role in the pathophysiology of the exercise limitation is discussed using a point-counterpoint approach. Future directions for research conclude the discussion...
  28. ncbi request reprint Skeletal muscle StO2 kinetics are slowed during low work rate calf exercise in peripheral arterial disease
    Timothy A Bauer
    Department of Medicine, University of Colorado at Denver Health Sciences Center, Box B 179, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Eur J Appl Physiol 100:143-51. 2007
    ....
  29. ncbi request reprint Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk
    Eric P Brass
    Department of Medicine, Section of Vascular Medicine, University of Colorado Health Sciences Center, Colorado Prevention Center, and National Jewish Medical and Research Center, Denver, 80203, USA
    Clin Pharmacol Ther 79:165-72. 2006
  30. doi request reprint Potential biomarkers of muscle injury after eccentric exercise
    Kathy E Sietsema
    Harbor UCLA Medical Center, Torrance, CA, USA
    Biomarkers 15:249-58. 2010
    ..ACT and C1 Inh peptides peaked earlier post-exercise than creatine kinase, and thus appear to provide new information on muscle response to injury...
  31. ncbi request reprint Exercise capacity as a predictor of survival among ambulatory patients with end-stage renal disease
    Kathy E Sietsema
    Harbor UCLA Research and Education Institute, Torrance, CA 90502, USA
    Kidney Int 65:719-24. 2004
    ..We analyzed the value of exercise capacity, characterized as peak oxygen uptake (VO2), for predicting survival in a cohort of 175 hemodialysis patients over a median follow-up of 39 months...
  32. ncbi request reprint Trends in antimicrobial drug development: implications for the future
    Brad Spellberg
    Research and Education Institute and Department of Medicine, Harbor University of California, Los Angeles Medical Center, Torrance, California 90502, USA
    Clin Infect Dis 38:1279-86. 2004
    ..Despite the critical need for new antimicrobial agents, the development of these agents is declining. Solutions encouraging and facilitating the development of new antimicrobial agents are needed...
  33. ncbi request reprint Differential management of cardiovascular disease in ESRD by nephrologists and cardiologists
    Hamik A Martirosyan
    Division of Nephrology and Hypertension, Harbor University of California, Los Angeles Research and Education Institute, Torrance, CA, USA
    Am J Kidney Dis 44:309-21. 2004
    ..The cardiovascular profile of patients with ESRD may differ from that of the general population. We examined how nephrologists and cardiologists differ in managing hypertension and cardiovascular disease in patients with ESRD...
  34. ncbi request reprint Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects)
    William R Hiatt
    Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, University of Colorado School of Medicine C O Colorado Prevention Center, Denver, CO 80203, USA
    J Vasc Surg 47:330-336. 2008
    ..At the time of approval, the United States Food and Drug Administration required an additional long-term safety study to evaluate the effect cilostazol on mortality...
  35. ncbi request reprint American and German students' knowledge, perceptions, and behaviors with respect to over-the-counter pain relievers
    Yaniv Hanoch
    Department of Health Services, UCLA School of Public Health, University of California Los Angeles, CA, USA
    Health Psychol 26:802-6. 2007
    ..The authors expected that the differences in access and marketing would affect knowledge and decision making related to OTCPRs in the United States and Germany...
  36. ncbi request reprint Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes
    Mark R Nehler
    University of Colorado Health Sciences Center and the Colorado Prevention Center, Denver, CO 80262 0302, USA
    J Vasc Surg 45:953-60; discussion 960-1. 2007
    ....
  37. ncbi request reprint Pulmonary VO2 dynamics during treadmill and arm exercise in peripheral arterial disease
    Timothy A Bauer
    Section of Vascular Medicine, University of Colorado Health Sciences Center, Box B 179, 4200 East Ninth Ave, Denver, CO 80262, USA
    J Appl Physiol 97:627-34. 2004
    ..Furthermore, the slowed pulmonary Vo(2) kinetics of the lower extremity could not be explained by any abnormalities in resting cardiac or pulmonary function and were not related to the magnitude of reduction in limb vascular reactivity...
  38. ncbi request reprint Impaired muscle oxygen use at onset of exercise in peripheral arterial disease
    Timothy A Bauer
    University of Colorado Health Sciences Center, Denver 80262, USA
    J Vasc Surg 40:488-93. 2004
    ..We hypothesized that at the onset of exercise the kinetics of StO2 desaturation would be slowed in PAD compared with control responses...
  39. ncbi request reprint Carnitine replacement in end-stage renal disease and hemodialysis
    Menotti Calvani
    Sigma Tau, Via Pontina Km 30, 00400 Pomezia, Rome, Italy
    Ann N Y Acad Sci 1033:52-66. 2004
    ..Furthermore, LC may positively influence the nutritional status of HD patients by promoting a positive protein balance, and by reducing insulin resistance and chronic inflammation, possibly through an effect on leptin resistance...